
The National Agency for Food and Drug Administration and Control (NAFDAC) has ordered the immediate withdrawal of multi-dose Artemether/Lumefantrine oral suspension from the market. This product is no longer approved for registration or use in Nigeria, as the agency aims to prevent potential health risks associated with its instability and inefficacy. NAFDAC had initially announced the issue in a public alert last year, but the product is still being found in circulation.
NAFDAC emphasized that the multi-dose oral suspension can lose its effectiveness over time, leading to inadequate treatment of malaria. This situation raises serious health concerns, especially since the suspension is often used by vulnerable populations. Manufacturers and importers of this product are now required to switch to more reliable options, such as dispersible tablets or single-dose sachets, to ensure patient safety.
In light of the ongoing circulation of these products, NAFDAC has directed zonal directors and state coordinators to intensify surveillance and remove any remaining stock from the market. Consumers and healthcare professionals are urged to report any cases of these products or any adverse effects related to their use. The agency remains committed to safeguarding public health by cracking down on unsafe and substandard medical products.

